dehydrogenase (DPD), the first and rate-limiting enzyme in the three-step catabolic pathway of endogenous pyrimidines, also metabolises pyrimidinebased anti-metabolites to relatively inactive products via this pathway [1, 2] , 5-Fluorouracil (5-FU), an antimetabolite structurally similar to uracil, was developed as an anti-cancer agent over four decades ago and remains the first-line therapy for patients with advanced colorectal cancer. This drug is also commonly used as part of combination therapy for the treatment of other solid tumours, such as breast and head/neck cancer and is the third most commonly prescribed chemotherapeutic agent [3] . 5-FU is a pro-drug and requires activation to nucleotide analogues (FdUMP, FdUTP and/or FdTTP) to exert its cytotoxic effects. Renal and hepatic clearance of 5-FU result in minimal amounts of an administered dose being available for conversion to active metabolites as approximately 10%-20% is excreted unchanged in the urine and over 80% is catabolised by DPD, predominantly in the liver [4] . Response rates to 5-FU therapy remain relatively low (20%-40%), at least in part due to the narrow therapeutic index and nonlinear kinetics of the drug which make it difficult to achieve a clinical response without producing significant systemic toxicity. DPD clearly plays a key role in 5-FU pharmacokinetics and prospective determination of DPD activity may identify patients likely to respond to fluoropyrimidine therapies.
Dihydropyrimidine dehydrogenase (DPD), the first and rate-limiting enzyme in the three-step catabolic pathway of endogenous pyrimidines, also metabolises pyrimidinebased anti-metabolites to relatively inactive products via this pathway [1, 2] , 5-Fluorouracil (5-FU), an antimetabolite structurally similar to uracil, was developed as an anti-cancer agent over four decades ago and remains the first-line therapy for patients with advanced colorectal cancer. This drug is also commonly used as part of combination therapy for the treatment of other solid tumours, such as breast and head/neck cancer and is the third most commonly prescribed chemotherapeutic agent [3] . 5-FU is a pro-drug and requires activation to nucleotide analogues (FdUMP, FdUTP and/or FdTTP) to exert its cytotoxic effects. Renal and hepatic clearance of 5-FU result in minimal amounts of an administered dose being available for conversion to active metabolites as approximately 10%-20% is excreted unchanged in the urine and over 80% is catabolised by DPD, predominantly in the liver [4] . Response rates to 5-FU therapy remain relatively low (20%-40%), at least in part due to the narrow therapeutic index and nonlinear kinetics of the drug which make it difficult to achieve a clinical response without producing significant systemic toxicity. DPD clearly plays a key role in 5-FU pharmacokinetics and prospective determination of DPD activity may identify patients likely to respond to fluoropyrimidine therapies. DPD activity demonstrates considerable variation in both healthy and cancer populations and 3%-5% of the population have reduced activity [5] . Reduced DPD activity is associated with severe gastrointestinal, neurological and haematological toxicity in cancer patients receiving 5-FU therapy [6] . At least 20 cases of severe 5-FU toxicity in DPD-deficient cancer patients have now been reported in the literature and an increasing number of unpublished cases have been detected by ourselves and others. Treatment of patients with toxicity is expensive and such adverse, sometimes life-threatening reactions can result in reduced patient compliance for further chemotherapy.
In addition to its involvement in the side-effects associated with 5-FU therapy, DPD may also play a role in sensitivity/resistance to therapy with fluoropyrimidines. 5-FU clearance correlates with DPD activity in peripheral blood mononuclear cells (PBMC) [7] and there is an increasing body of evidence that relates 5-FU plasma concentration to both the toxicity and the clinical efficacy of the drug in cancer patients [8] [9] [10] . Several studies demonstrate that DPD expression is correlated with resistance or inversely correlated with degree of sensitivity of gastrointestinal, breast and head and neck cancer cell lines to 5-FU [11] [12] [13] . DPD activity and mRNA levels are also inversely correlated with 5-FU sensitivity of human tumour xenografts [14] . In addition, the efficacy of the 5-FU pro-drug capecitabine and its metabolite 5'-deoxy-5-fluorouridine are correlated with the relative activities of the pyrimidine anabolic (thymidine phosphorylase) and catabolic pathways (DPD) in human cancer xenografts [15] . In a study of advanced head and neck cancer patients, tumour DPD activity tended to be lower in complete responders compared to non-responders or those achieving only a partial response to 5-FU therapy [16] . In addition, patients with reduced DPD activity in head and neck tumour tissue compared to the adjacent uninvolved tissue had a significantly better response to 5-FU therapy compared to those patients with higher catabolism in the tumour tissues [17] . These data suggest that cancer patients with high DPD activity, particularly within the tumour, may be at an increased risk of treatment failure in response to fluoropyrimidine therapy.
DPD clearly plays a critical role in a patient's response to therapy with fluoropyrimidines. This raises the question whether the DPD status of an individual should be determined prior to treatment in order to individualise 5-FU based therapies. DPD activity is most frequently measured in PBMC, an easily obtainable tissue that correlates with activity in the liver [18] . However, DPD activity assays are expensive, labourintensive and the expertise necessary to perform this analysis is usually not widely available. In addition to these disadvantages, previous studies suggest that although measurement of PBMC DPD activity is useful for the detection of patients at risk of toxicity in response to 5-FU, it is not useful for predicting tumour DPD activity [19] , a factor that may directly influence a patient's clinical response to this agent.
Alternative strategies use DPD mRNA or protein analysis. Measurement of DPD mRNA levels using a variety of techniques has been suggested as a costeffective and rapid means of determining tumour DPD phenotype. Previous studies demonstrate that although DPD mRNA levels are reduced in colon tumours compared to the adjacent uninvolved mucosa, DPD activity is not reduced in the neoplastic tissues, indicating translation may be enhanced in the tumour [20, 21] . It is reported by Takenoue et al. in this issue that DPD protein levels do not correlate well with mRNA levels in colorectal tumour tissues [22] . These data further question the clinical utility of measuring DPD mRNA levels.
In this issue Takenoue et al. [22] report the use of immunohistochemistry to measure DPD protein levels in formalin-fixed, paraffin embedded colon carcinoma samples. These tissues are readily available following tumour resection and a good correlation was demonstrated between immunohistochemical score and protein levels measured by Western analysis, which in turn correlated well with DPD activity. Significant variation in DPD activity occurs in the population and DPD plays a key role in 5-FU pharmacokinetics thereby providing a rationale for measurement of DPD in patients prior to treatment. Immunohistochemistry provides a widely applicable assay for large-scale screening of cancer patients who are to receive 5-FU.
The recent development of a number of DPD inhibitors provides an alternative approach that may allow improved pharmacokinetic control and effective dosing of 5-FU based therapies [2] . Pre-clinical and clinical studies utilising DPD inhibitors such as eniluracil, demonstrate that 5-FU therapy can be standardised and the clinically effective dose can be reduced (approximately 300-fold) through inhibition of pyrimidine catabolism in normal and neoplastic tissues [23, 24] . A combination agent, S-l which contains a 5-FU pro-drug (tegafur), a reversible DPD inhibitor (5-chloro-2,4-hydroxypyridine) and a phosphoribosyl pyrophosphate transferase inhibitor (potassium oxanate), has been shown to improve the tumour selective toxicity and reduce systemic toxicities associated with 5-FU in rat colorectal xenograft models [25, 26] . S-l also demonstrated some anti-tumour activity (49% response rate) in a phase II trial of advanced gastric cancer patients [27] . An oral fluoropyrimidine, Orzel which contains UFT (tegafur and uracil, a DPD inhibitor) administered in combination with leucovorin, is well-tolerated and demonstrates anti-cancer activity in metastatic head/ neck and breast cancer trials [28] . These inhibitors are, however, not tumour-specific and development of agents that directly inhibit tumoural DPD activity is more likely to improve the therapeutic index of 5-FU by reducing inactivation in the tumour while maintaining the catabolic pathways in normal tissues. An individual's response to the pro-drug 5-FU is clearly regulated by DPD levels in vivo. Information in the literature provides further stimulus to investigate the specific role normal and tumour tissue DPD levels play in clinical responses to 5-FU therapy. Immunohistochemistry on fixed tumour tissues provides a rapid, cost-effective and widely applicable system suitable for determination of tumour DPD levels prior to the onset of chemotherapy. Controlled, prospective clinical trials with larger patient numbers are required to establish the therapeutic advantage of pre-treatment DPD screening to optimise 5-FU therapy. 
